Abstract 307P
Background
Uterine leiomyosarcoma (uLMS) is a rare, aggressive subtype of uterine cancer. Metastatic uLMS is known for its poor prognosis. uLMS have recurrence rates of 50-70%, with an overall 5-year survival less than 15% in advanced stages. The main treatment for localized uLMS is surgery. For unresectable or advanced uLMS, other options such as chemotherapy and hormonal therapy can be offered.
Methods
We conducted a search across 5 databases, Google Scholar, Science Direct, PubMed, EMBASE & Scopus for studies within the last 15 years. We included studies that recorded combination chemotherapy/hormonal therapy as the treatment regime for histologically confirmed metastatic/unresectable uLMS. We excluded studies with <5 samples, those that included other uterine cancers & non-English articles. Quality of the studies were assessed by the Newcastle-Ottawa Scale (NOS).
Results
We found 10 studies, with a total of 427 metastatic uLMS patients. Combination chemotherapy had much higher rates of response & progression-free survival compared to hormonal therapy. Gemcitabin-docetaxel was the most common regime, with high effectivity. Addition of targeted therapy did not improve outcomes significantly. However, combination chemotherapy had a much higher proportion of grade 3-4 toxicity. Most common side effects were myelosuppression, fatigue & liver toxicity, resulting in much higher rates of therapy discontinuation due to the side effects. Hormonal therapy was much more tolerable, with common side effects including hot flashes, weight gain, muscle pain & joint pain. Unfortunately, hormonal therapy had higher proportions of therapy discontinuation due to disease progression, and had lower response rates, shorter overall survival & progression-free survival. Overall, patient-specific factors play a crucial role in treatment decisions. Hormonal therapy has a more attractive side effect profile, while combination chemotherapy though more aggressive may be favorable in cases requiring rapid tumor control.
Conclusions
uLMS is an aggressive cancer with hormonal therapy & combination chemotherapy as treatment options. Hormonal therapy has a better side effect profile, with chemotherapy having better effectivity and survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Angel.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract